Results 121 to 130 of about 1,122,477 (316)
Molecular Oncology, EarlyView.The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song +11 more
wiley +1 more source
An Orthotopic Model of Uveal Melanoma in Zebrafish Embryo: A Novel Platform for Drug Evaluation. [PDF]
Biomedicines, 2021 Tobia C +7 more
europepmc +1 more source
Molecular Oncology, EarlyView.In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton +17 more
wiley +1 more source
A Bioprinted Heart-on-a-Chip with Human Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Evaluation. [PDF]
Bioengineering (Basel), 2022 Faulkner-Jones A +6 more
europepmc +1 more source
Evaluation of drug dependence treatment in VA hospitals. [PDF]
, 1978 Theodore W. Lorei +2 more
openalex +1 more source
Molecular Oncology, EarlyView.Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop +10 more
wiley +1 more source
Drug Evaluation Based on a Multi-Channel Cell Chip with a Horizontal Co-Culture. [PDF]
Int J Mol Sci, 2021 Kim GJ, Lee KJ, Choi JW, An JH.
europepmc +1 more source
EVALUATION OF CARDIAC DRUGS IN THE PRESENCE OF AN ELECTRICAL PACEMAKER
, 1964 P Grondin +4 more
openalex +1 more source
Molecular Oncology, EarlyView.Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed +8 more
wiley +1 more source